Sarah Pinkston, NP
Acute Care · Mount Carmel, ILNPI 1861918559
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.9% of the total across 222 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 222 payments — averaging $21.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$571
- Seagen Inc.$549
- Daiichi Sankyo Inc.$435
- Johnson & Johnson$362
- AstraZeneca$281
- E.r. Squibb & Sons, L.L.C.$276
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,37091%
- Education$4399%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 27 | $571 |
| Seagen Inc. | 20 | $549 |
| Daiichi Sankyo Inc. | 20 | $435 |
| Johnson & Johnson | 16 | $362 |
| AstraZeneca | 13 | $281 |
| E.r. Squibb & Sons, L.L.C. | 12 | $276 |
| Merck | 15 | $250 |
| Amgen | 9 | $195 |
| Lilly USA, LLC | 11 | $176 |
| Pfizer | 10 | $164 |
| Tempus AI, Inc | 4 | $163 |
| Sanofi | 8 | $139 |
| Regeneron Healthcare Solutions, Inc. | 6 | $136 |
| Jazz Pharmaceuticals Inc. | 5 | $127 |
| Astellas Pharma US Inc | 4 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $86 |
| Beigene USA, Inc. | 3 | $85 |
| Genentech USA, Inc. | 4 | $78 |
| Mirati Therapeutics, Inc. | 4 | $77 |
| Sobi, Inc | 4 | $76 |
| Teva Pharmaceuticals USA, Inc. | 2 | $67 |
| Incyte Corporation | 1 | $59 |
| EMD Serono, Inc. | 3 | $58 |
| Gilead | 3 | $56 |
| Puma Biotechnology, Inc. | 2 | $41 |
| Taiho Oncology, Inc. | 2 | $36 |
| Servier Pharmaceuticals LLC | 2 | $30 |
| ADC Therapeutics America, Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Beone Medicines USA, Inc. | 1 | $20 |
| Bristol Myers Squibb | 1 | $17 |
| Exelixis Inc. | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| AbbVie | 1 | $16 |
| Deciphera Pharmaceuticals Inc. | 1 | $16 |
How this compares
$4,809 in reported general payments places this provider in the 95th percentile of 461 acute care providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 17 | $370,263 |
| RevlimidLenalidomide | 13 | $299,390 |
| ImbruvicaIbrutinib | 15 | $230,656 |
| VenclextaVenetoclax | 11 | $161,091 |
| OxycontinOxycodone Hcl | 11 | $3,389 |
| Anastrozole | 76 | $877 |
| Ondansetron OdtOndansetron | 17 | $395 |
| Doxycycline Hyclate | 15 | $364 |
| Tamoxifen Citrate | 18 | $353 |
| Lidocaine Hcl ViscousLidocaine Hcl | 20 | $338 |
| Prochlorperazine Maleate | 32 | $323 |
| Ondansetron Hcl | 63 | $290 |
| Oxycodone Hcl | 31 | $282 |
| Pantoprazole Sodium | 12 | $265 |
| Gabapentin | 20 | $247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $276 | $370,26317 claims |
| Bristol Myers SquibbRevlimid | $17 | $299,39013 claims |
| AbbVieVenclexta | $16 | $161,09111 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $67 | $19825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 461 acute care providers in Illinois.
Other acute care in Mount Carmel
- Tedra GrayChicago$78K
- Lynn HickmanArlington Heights$61K
- Gwen CassidyChicago$46K
- Laura CoyleOak Lawn$34K
- Erin DarguzasChicago$17K
- Amy BatesQuincy$14K
- Sarah MiyataChicago$11K
- Katie MeadorChicago$10K
- Dena PelletreauArlington Heights$9K
- Pamela KontosHazel Crest$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.